F S&P 500
5,250.25 +4.00 (+0.08%) F Dow Jones
39,654.00 +12.00 (+0.03%) F Nasdaq
18,279.75 +24.75 (+0.14%) E-mini Russell 2000 Index Futur
2,073.70 +5.80 (+0.28%) Petróleo
78.57 +0.31 (+0.40%) Oro
2,353.70 -21.30 (-0.90%)
FOXO Technologies Inc. (FOXO)
Antes de la apertura del mercado:
FOXO Technologies Inc.
729 North Washington Avenue
Suite 600
Minneapolis, MN 55401
United States
612 562 9447
https://foxotechnologies.com
Sector(es): Healthcare
Industria: Health Information Services
Empleados a tiempo completo: 4
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Mark Brian White | Interim CEO & Director | N/D | N/D | 1960 |
| Mr. Martin Christopher Ward FCA | Interim Chief Financial Officer | N/D | N/D | 1957 |
| Mr. Jim Grauel Jr. | Chief Distribution Officer | N/D | N/D | N/D |
| Ms. Susan Neo | Chief Security Officer | N/D | N/D | N/D |
Descripción
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.
Gestión corporativa
La calificación ISS Governance QuickScore de FOXO Technologies Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
